Contact Us

Web Copyright: Shijiazhuang No.4 Pharmaceutical Co., Ltd.    Powered by www.300.cn   冀ICP备05007979号-1

Add: No.518,East Huai'an Road, High-tech Industrial

Development,Shijiazhuang, Hebei, China
Web: www.sjzsiyao.com
Tel: 86 311 67167137 / 67167144
E-mail:
trade@sjzsiyao.com / chinainfusion@163.com
Skype: xlmamary

About Us

Contact us!

Online Message

可信组件
>
products
>
Argatroban Injection

products

Product name

Argatroban Injection

NO.
没有此类产品
I want to make an inquiry
Product description

Name:Argatroban Injection

Specificationinjection 2ml10mg

Approval NumberState Drug Administration: H20233354

Usage and dosage

1. It is used for the improvement of neurological symptoms (motor paralysis), daily activities (walking, standing, sitting, eating) in patients in the acute phase of ischemic cerebral infarction within 48 hours of onset. The improvement of the daily activities (walking, standing, sitting, eating and drinking).

Usually for adults, 6 doses (60mg of Argatroban) diluted with appropriate amount of infusion are administered intravenously for 24 hours during the first 2 days, and 2 doses (20mg of Argatroban) diluted with appropriate amount of infusion are administered once a day in the morning and once in the evening (10mg of Argatroban) during the next 5 days, and once in 3 hours. It may be increased or decreased according to age and symptoms. Please do so under medical supervision.

2. For the improvement of ulcers, rest pain and coldness in the extremities of patients with chronic arterial occlusive disease (thromboembolic vasculitis, occlusive arteriosclerosis). The usual dosage for adults is one dose (Argatroban 10mg) twice a day (Argatroban 20mg), which is diluted with infusion solution and administered intravenously for 2 to 3 hours each time. The dosage may be increased or decreased according to age and symptoms. Please do so under the guidance of your doctor.

3. Note: For patients with chronic arterial occlusive disease, there is insufficient experience in administering this product for a duration of more than 4 weeks.

 

Indications1. Used in the acute phase of ischemic cerebral infarction within 48 hours of onset of neurological disorders 2. Used in the improvement of extremity ulcers, rest pain and cold sensation in patients with chronic arterial occlusive disease (thrombo-occlusive vasculitis, occlusive arteriosclerosis)

Indication:

Corresponding parameter set not found, please add it in property template of background
暂未实现,敬请期待
暂未实现,敬请期待